Media Sera and Reagents Cell Culture market to achieve an exponential growth rate.

Pune, India, August, 2018/MRFR Press Release/- Market Research Future published a half-cooked research report on “Global Media Sera and Reagents Cell Culture Market Research Report - Forecast to 2023– Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.

The global market consists of players such as Thermo Fisher Scientific, Inc., Merck KGaA, GE Healthcare, Lonza Group AG, Becton, Dickinson and Company, Corning, Inc., Eppendorf AG, Hi-Media Laboratories, Sartorius AG, and Promocell GmbH are some of the prominent players at the forefront of competition in the global media sera and reagents market and are profiled in MRFR Analysis report.

Global Media Sera and Reagents Cell Culture Market   - Overview

Media sera and reagents cell culture are consumables used in cell culture. These media sera and reagents cell culture provides artificial environment for the growth of the cell by providing essential nutrients.

The market for media sera and reagents cell culture is growing a healthy growth due to a host of factors such as increasing incidence of chronic diseases, growth in the number of regulatory approvals for cell culture-based vaccines, and evolution of genetic engineering, artificial organs, and recombinant DNA technology, amongst others have driven this market. Additionally, rising demand for well-developed healthcare sector is pushing the growth of media sera and reagents cell culture market. Similarly, growth strategies such as new product innovation, and merger & acquisition activities taken up by major market players are likely to enhance the growth of media sera and reagents cell culture market.

For instance, according to National cancer institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. Similarly, in 2016, U.S. spent over USD 125 billion for cancer care and is expected to spend over USD 156 billion by 2020.This rising case in chronic diseases are likely to enhance the growth of media sera and reagents cell culture market.

However, factors such as high cost and lack of infrastructure for cell-based research are likely to hamper the growth of media sera and reagents cell culture market.

Thermo Fisher Scientific Inc.

Founded on 1956 and headquartered at United States, Thermo Fisher offers analytical instruments, equipment, reagents and consumables for research, manufacturing, analysis, discovery, and diagnosis. The company has focused on various inorganic and organic growth strategies to enhance its product portfolio and gain foothold in various geographies. For instance, in the year 2017, Thermo Fisher Scientific entered into an partnership with Juno Therapeutics to use Thermo Fisher's Cell Therapy Systems (CTS) activation reagents in the manufacturing of its chimeric antigen receptor T cell therapies. These partnership increases the firm’s customer base and widens the company’s already existing wide product portfolio. Additionally, in 2014, Thermo Fisher completed acquisition of Life Technologies Corporation. This acquisition aims to enhance the firm’s customer base and widens its geographic presence.

Access Report @ https://www.marketresearchfuture.com/reports/media-sera-and-reagents-cell-culture-market-1170

GE Healthcare

Headquartered at U.K., GE Healthcare, offers a wide range of device based medical products. The firm offers its products all over the world. The firm has focused on various growth strategies such as expansions, product launches, acquisition and collaboration to enhance its product portfolio and widen its foothold in various geographies. For instance, in 2014, the firm acquired Thermo Fisher Scientific’s HyClone cell culture media, sera and process liquids. This acquisition aims to widen the firm’s already existing wide range of products. Additionally, in 2016, GE Healthcare entered into an agreement with STEMCELL Technologies Inc. to provide T-Cell reagents for commercial-scale cell therapy production. This agreement and acquisition enhance the firm’s product portfolio and business across different geographies.

Regional Analysis

The media sera and reagents cell culture market is segmented based on regions into Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas region has been dominant over the years in terms of market sizing of the market. The highly developed Life Science industry in the US, and presence of large number of companies in the region is one of the prime factors responsible for the growth of the American market. Moreover, increase in the rate of the chronic diseases over the last decade, increased government support and funding for cell-based research, automation of the research industry has been a great boost in the growth of the media sera and reagent cell culture market in the American region.

European region has also observed an exponential growth in the market. Expansion of the major companies in the European region, increased product approval, growing prevalence of chronic diseases, rising geriatric population susceptible to various chronic conditions, and eventually rising patient population and rising healthcare expenditure are some of the growth factors in the European region. According to Eurostat, older population in Europe is expected to rise from 5.45% in 2016 to 12.7% by 2080. This rising older population and growing patient population is likely to enhance the growth of media sera and reagents cell culture market in Europe.

Asia pacific region is expected to be fastest growing region in media sera and reagents cell culture market owing to its growing population and increasing healthcare expenditure and demand for new treatment options. Apart from that, increased investments by big players in the Asian countries such as India and China may fuel the growth of the market in this region.

On the other hand, the Middle East & Africa is expected to witness limited growth due to limited access to the healthcare resources and lack of awareness about rare diseases. In the Middle East, the growth of the market is driven by increasing availability new diagnostic and treatment methods.